Fulcrum Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview

Fulcrum Therapeutics

23/02/2024 14:06

* Fulcrum Therapeutics Inc  FULC.OQ   FULC.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
27 for the period ending December 31 2023
    * The Cambridge Massachusetts-based  company is expected to
report
a 32.7% decrease in revenue to $461.17 thousand from $685
thousand a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Fulcrum Therapeutics Inc
is
for a loss of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fulcrum
Therapeutics Inc is $11.00​, above​ its last closing price
of $9.55. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.43       -0.43      -0.39     Beat    10.3
 Jun. 30 2023  -0.45       -0.44      -0.38     Beat    14.5
 Mar. 31 2023  -0.47       -0.46      -0.41     Beat    10​
 Dec. 31 2022  -0.51       -0.49      -0.50     Missed  -2.1
 ​​Sep.        -0.62       -0.61      -0.51     Beat    16.7
 30 2022                                                
 Jun. 30 2022  -0.66       -0.66      -0.83     Missed  -25.6​
 Mar. 31 2022  -0.62       -0.63      -0.64     Missed  -2.1
 Dec. 31 2021  -0.71       -0.73      -0.58     Beat    20.3
 This summary was machine generated February 23 at 14:05 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)